Research Article Details
| Article ID: | A20534 |
| PMID: | 25906652 |
| Source: | Lik Sprava |
| Title: | [State of intestinal microbiota in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease]. |
| Abstract: | High prevalence of type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD) contributes to the intensification of scientific research the aim of which is to improve existing treatment. It is given the data about the state of intestinal microbiota in 64 patients with type 2 DM and NAFLD, 26 patients with type 2 DM and 28--with NAFLD. The research revealed significant changes in microbiota composition in patients with type 2 DM combined with NAFLD. Decompensated dysbiosis was registered in 71.9% of patients in this group which manifested in increased quantitative indicators of transient microflora crop with pathogenic characteristics and lack of microflora with protective characteristics. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|